Vaccine effectiveness is now common place in the news and every day conversation. In the vaccine development space, demonstration of the of vaccine efficacy is pivotal to obtain the authorization from the regulatory agencies to proceed with the commercialization. Preparation for an efficacy study to support begins much earlier. To be best prepared to support the biopharmaceutical industry or address a new infectious diseases, experts must understand the vaccine designs and associated mechanism of action to initiate the assay method development. For Dr. Luc Gagnon, PhD, and Dr. Bassam Hallis, PhD, virologists and infectious disease experts, this mindset and understanding of viral and bacterial pathogens are core tenants of their careers.
During this discussion, our experts will answer questions on the significance of the key assays to support prophylactic vaccine development as well as the worldwide impact of an effective, commercially viable vaccine. Woven into this conversation, a perspective of how a specialty laboratory operates to carry out a sponsor’s study and why these experts work in consultation with sponsors to design and develop the most optimal study. It’s a master class in scientific transparency as it relates to addressing infectious diseases.
We invite virologists, infectious disease experts, and scientists in the vaccine field to participate in an open forum to discuss the vaccine development landscape.